RxDoctor Payments DataLook up a doctor →

Amanda Small, APRN

Nurse Practitioner · Tulsa, OKNPI 1104290071

Payments from drug & device makers

$14,255in general payments, 2019–2025

Across 885 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • GSK$787
  • Merck$707
  • Lilly USA, LLC$700
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$14,17099%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie163$2,103
Novo Nordisk88$1,345
Pfizer59$1,015
GSK63$787
Merck46$707
Lilly USA, LLC45$700
AstraZeneca33$667
Amgen45$664
Astellas Pharma US Inc24$604
Boehringer Ingelheim30$564
Abbott30$456
Bayer24$434
Johnson & Johnson22$322
Otsuka America Pharmaceutical, Inc.17$312
Takeda Pharmaceuticals U.S.A., Inc.16$286
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$234
Intra-sana Laboratories4$203
Exact Sciences13$195
Kowa Pharmaceuticals America, Inc.11$174
Eisai Inc.8$152
Idorsia Pharmaceuticals US Inc8$149
Novartis10$142
Sumitomo Pharma America, Inc.5$120
Esperion Therapeutics, Inc.6$116
Axsome Therapeutics, Inc.4$102
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$97
Currax Pharmaceuticals LLC6$92
Dexcom, Inc.4$91
Biogen5$84
Phathom Pharmaceuticals, Inc.5$82
Almatica Pharma LLC5$82
Biohaven Pharmaceuticals, Inc.5$73
Corium, LLC4$73
Lundbeck LLC3$66
Amarin Pharma, Inc.4$63
Inogen, Inc.5$62
Daiichi Sankyo Inc.3$62
Avanir Pharmaceuticals, Inc.2$60
Teva Pharmaceuticals USA, Inc.3$59
Antares Pharma, Inc.4$59
Aimmune Therapeutics, Inc.2$50
E.r. Squibb & Sons, L.L.C.3$50
Nabriva Therapeutics, PLC3$49
Biohaven Pharmaceutical Holding Company Ltd.3$42
Ultragenyx Pharmaceutical Inc.2$42
Althera Pharmaceuticals LLC3$40
Genentech USA, Inc.2$34
Scilex Pharmaceuticals Inc.2$31
Nestle Healthcare Nutrition Inc.2$28
Clarus Therapeutics Inc.2$28
Boston Scientific1$23
Sanofi Pasteur Inc.1$23
Azurity Pharmaceuticals, Inc.1$21
Xeris Pharmaceuticals, Inc.1$20
Abiomed1$20
Seqirus USA Inc1$19
Medicure Pharma Inc.1$17
Sanofi-aventis U.S. LLC1$17
Arbor Pharmaceuticals, Inc.1$17
Endo Pharmaceuticals Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,255 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Medicare billing

Part B allowed, 2024
$82,183
Medicare patients
664
Services billed
1,520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$48,981
OzempicSemaglutide42$37,286
MounjaroTirzepatide29$28,850
JanuviaSitagliptin Phosphate21$23,255
JardianceEmpagliflozin14$21,573
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$18,908
XareltoRivaroxaban13$18,786
Synjardy XrEmpagliflozin/Metformin Hcl19$16,930
TrulicityDulaglutide12$16,420
LinzessLinaclotide16$14,517
MyrbetriqMirabegron27$13,831
GemtesaVibegron13$6,914
Breo ElliptaFluticasone/Vilanterol16$6,799
Ezetimibe43$3,026
Estradiol44$2,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,015$48,98155 claims
Lilly USA, LLCMounjaro, Trulicity$700$45,27041 claims
Boehringer IngelheimJardiance, Synjardy Xr$564$38,50333 claims
Novo NordiskOzempic$1,345$37,28642 claims
GSKTrelegy Ellipta, Breo Ellipta$787$25,70741 claims
MerckJanuvia$707$23,25521 claims
Johnson & JohnsonXarelto$322$18,78613 claims
AbbVieLinzess$2,103$14,51716 claims
Astellas Pharma US IncMyrbetriq$604$13,83127 claims
Sumitomo Pharma America, Inc.Gemtesa$120$6,91413 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$59$2,25811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →